Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

Schrag, 2006, Heterogeneity of Parkinson's disease, J Neurol Neurosurg Psychiatry, 77, 275, 10.1136/jnnp.2005.074393 Kantarci, 2006, Epidemiology and natural history of multiple sclerosis: new insights, Curr Opin Neurol, 19, 248, 10.1097/01.wco.0000227033.47458.82 Flachenecker, 2006, Epidemiology of neuroimmunological diseases, J Neurol, 253, v2, 10.1007/s00415-006-5001-3 Valcour, 2006, HIV infection and dementia in older adults, Clin Infect Dis, 42, 1449, 10.1086/503565 McArthur, 2004, HIV dementia: an evolving disease, J Neuroimmunol, 157, 3, 10.1016/j.jneuroim.2004.08.042 Mayeux, 2003, Epidemiology of neurodegeneration, Annu Rev Neurosci, 26, 81, 10.1146/annurev.neuro.26.043002.094919 Liu, 2003, Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention, J Pharmacol Exp Ther, 304, 1, 10.1124/jpet.102.035048 Corti, 2005, Parkinson's disease: from causes to mechanisms, C R Biol, 328, 131, 10.1016/j.crvi.2004.10.009 Gendelman, 2002, Neural immunity: friend or foe?, J Neurovirol, 8, 474, 10.1080/13550280290168631 Bhanu Prakash, 2006, Identification, segmentation, and image property study of acute infarcts in diffusion-weighted images by using a probabilistic neural network and adaptive gaussian mixture model, Acad Radiol, 13, 1474, 10.1016/j.acra.2006.09.045 Prinster, 2006, Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study, Neuroimage, 29, 859, 10.1016/j.neuroimage.2005.08.034 Robichaud, 2006, Approaches to palliative therapies for Alzheimer's disease, Curr Top Med Chem, 6, 553, 10.2174/156802606776743039 Weissig, 2006, Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria, J Liposome Res, 16, 249, 10.1080/08982100600851169 Collister, 2005, Potential therapeutic targets in the NF-kappaB pathway for Alzheimer's disease, Drug News Perspect, 18, 623, 10.1358/dnp.2005.18.10.959576 Bruijn, 2006, Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies, Expert Rev Neurother, 6, 417, 10.1586/14737175.6.3.417 Tyler, 2006, CNS gene therapy and a nexus of complexity: systems and biology at a crossroads, Cell Transplant, 15, 267, 10.3727/000000006783982007 Pardridge, 2005, The blood–brain barrier: bottleneck in brain drug development, NeuroRx, 2, 3, 10.1602/neurorx.2.1.3 Kingsley, 2006, Nanotechnology: A focus on nanoparticles as a drug delivery system, J Neuroimmunol Pharmacol, 1, 340, 10.1007/s11481-006-9032-4 Kabanov, 2004, New technologies for drug delivery across the blood brain barrier, Curr Pharm Des, 10, 1355, 10.2174/1381612043384826 Spector, 2000, Drug transport in the mammalian central nervous system: multiple complex systems. A critical analysis and commentary, Pharmacology, 60, 58, 10.1159/000028349 Alyaudtin, 2001, Interaction of poly(butylcyanoacrylate) nanoparticles with the blood–brain barrier in vivo and in vitro, J Drug Target, 9, 209, 10.3109/10611860108997929 Pardridge, 2002, Targeting neurotherapeutic agents through the blood–brain barrier, Arch Neurol, 59, 35, 10.1001/archneur.59.1.35 Cornford, 2002, New systems for delivery of drugs to the brain in neurological disease, Lancet Neurol, 1, 306, 10.1016/S1474-4422(02)00136-9 Pardridge, 2002, Drug and gene delivery to the brain: the vascular route, Neuron, 36, 555, 10.1016/S0896-6273(02)01054-1 Misra, 2003, Drug delivery to the central nervous system: a review, J Pharm Pharm Sci, 6, 252 Begley, 2004, Delivery of therapeutic agents to the central nervous system: the problems and the possibilities, Pharmacol Ther, 104, 29, 10.1016/j.pharmthera.2004.08.001 Kas, 2004, Drug delivery to brain by microparticulate systems, Adv Exp Med Biol, 553, 221, 10.1007/978-0-306-48584-8_17 Banks, 2002, Strategies for the delivery of leptin to the CNS, J Drug Target, 10, 297, 10.1080/10611860290031895 Loscher, 2005, Drug resistance in brain diseases and the role of drug efflux transporters, Nat Rev Neurosci, 6, 591, 10.1038/nrn1728 Roney, 2005, Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease, J Control Release, 108, 193, 10.1016/j.jconrel.2005.07.024 Liu, 2005, Strategies to optimize brain penetration in drug discovery, Curr Opin Drug Discovery Dev, 8, 505 Gaillard, 2005, Targeted delivery across the blood–brain barrier, Expert Opin Drug Deliv, 2, 299, 10.1517/17425247.2.2.299 Liu, 2005, Nanoparticle and other metal chelation therapeutics in Alzheimer disease, Biochim Biophys Acta, 1741, 246, 10.1016/j.bbadis.2005.06.006 Garcia-Garcia, 2005, Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain?, Int J Pharm, 298, 274, 10.1016/j.ijpharm.2005.03.031 Silva, 2006, Neuroscience nanotechnology: progress, opportunities and challenges, Nat Rev Neurosci, 7, 65, 10.1038/nrn1827 Dauer, 2003, Parkinson's disease: mechanisms and models, Neuron, 39, 889, 10.1016/S0896-6273(03)00568-3 Ohira, 2006, Risk factors for ischemic stroke subtypes: the atherosclerosis risk in communities study, Stroke, 37, 2493, 10.1161/01.STR.0000239694.19359.88 Zoccolella, 2006, Signs and symptoms at diagnosis of amyotrophic lateral sclerosis: a population-based study in southern Italy, Eur J Neurol, 13, 789, 10.1111/j.1468-1331.2006.01384.x Qureshi, 2006, Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS), Amyotroph Lateral Scler, 7, 173, 10.1080/14660820600640596 Shaw, 2005, Molecular and cellular pathways of neurodegeneration in motor neurone disease, J Neurol Neurosurg Psychiatry, 76, 1046, 10.1136/jnnp.2004.048652 Meltzer, 1992, Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease, Curr Top Microbiol Immunol, 181, 239 Luo, 2003, Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment, Neurology, 60, 1931, 10.1212/01.WNL.0000064396.54554.26 Zheng, 2001, HIV-1 infected and immune competent mononuclear phagocytes induce quantitative alterations in neuronal dendritic arbor: relevance for HIV-1-associated dementia, Neurotox Res, 3, 443, 10.1007/BF03033203 Kadiu, 2005, Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases, Neurotox Res, 8, 25, 10.1007/BF03033818 Anderson, 2002, HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes, J Acquired Immune Defic Syndr, 31, S43, 10.1097/00126334-200210012-00004 Gendelman, 1997, The neuropathogenesis of the AIDS dementia complex, Aids, 11, S35 Cotter, 1999, Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity, J Leukoc Biol, 65, 416, 10.1002/jlb.65.4.416 Ciborowski, 2006, Human immunodeficiency virus-mononuclear phagocyte interactions: emerging avenues of biomarker discovery, modes of viral persistence and disease pathogenesis, Curr HIV Res, 4, 279, 10.2174/157016206777709474 Lipton, 1995, Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome, N Engl J Med, 332, 934, 10.1056/NEJM199504063321407 Gendelman, 1989, The macrophage in the persistence and pathogenesis of HIV infection, Aids, 3, 475, 10.1097/00002030-198908000-00001 Ghorpade, 2001, Mononuclear phagocyte differentiation, activation, and viral infection regulate matrix metalloproteinase expression: implications for human immunodeficiency virus type 1-associated dementia, J Virol, 75, 6572, 10.1128/JVI.75.14.6572-6583.2001 Jiang, 2001, Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages, J Neuroimmunol, 117, 97, 10.1016/S0165-5728(01)00315-0 Poluektova, 2005, Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis, Glia, 52, 344, 10.1002/glia.20253 Cole, 2004, NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models, Ann N Y Acad Sci, 1035, 68, 10.1196/annals.1332.005 Moreira, 2006, Therapeutic options in Alzheimer's disease, Expert Rev Neurother, 6, 897, 10.1586/14737175.6.6.897 Dou, 2004, Neuroprotective strategies for HIV-1 associated dementia, Neurotox Res, 6, 503, 10.1007/BF03033447 Fellgiebel, 2006, CNS manifestations of Fabry's disease, Lancet Neurol, 5, 791, 10.1016/S1474-4422(06)70548-8 Jeyakumar, 2005, Storage solutions: treating lysosomal disorders of the brain, Nat Rev Neurosci, 6, 713, 10.1038/nrn1725 Neumann, 2006, Microglia: a cellular vehicle for CNS gene therapy, J Clin Invest, 116, 2857, 10.1172/JCI30230 Watson, 2006, Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice, Gene Ther, 13, 917, 10.1038/sj.gt.3302735 Liu, 2007, Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS, Mol Ther, 15, 242, 10.1038/sj.mt.6300016 Kim, 2007, Genetically engineered human neural stem cells for brain repair in neurological diseases, Brain Dev, 29, 193, 10.1016/j.braindev.2006.07.012 Au WL, et al. Neuroimaging in Parkinson's disease. J Neural Transm Suppl 2006:241–8. Mosconi, 2005, Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD, Eur J Nucl Med Mol Imaging, 32, 486, 10.1007/s00259-005-1762-7 Boska, 2004, Advances in neuroimaging for HIV-1 associated neurological dysfunction: clues to the diagnosis, pathogenesis and therapeutic monitoring, Curr HIV Res, 2, 61, 10.2174/1570162043485095 Tucker, 2004, Neuroimaging in human immunodeficiency virus infection, J Neuroimmunol, 157, 153, 10.1016/j.jneuroim.2004.08.036 Dhib-Jalbut, 2006, Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases, J Neuroimmunol, 176, 198, 10.1016/j.jneuroim.2006.03.027 Bocti, 2006, Topographical patterns of lobar atrophy in frontotemporal dementia and Alzheimer's disease, Dement Geriatr Cogn Disord, 21, 364, 10.1159/000091838 Kuwabara, 2004, Advance of SPECT: differential diagnosis and evaluation of pathophysiology of neurodegenerative disorders, Rinsho Shinkeigaku, 44, 894 Silverman, 2005, PET imaging in the assessment of normal and impaired cognitive function, Radiol Clin North Am, 43, 67, 10.1016/j.rcl.2004.09.012 Wearne, 2005, New techniques for imaging, digitization and analysis of three-dimensional neural morphology on multiple scales, Neuroscience, 136, 661, 10.1016/j.neuroscience.2005.05.053 Machulda, 2003, Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients, Neurology, 61, 500, 10.1212/01.WNL.0000079052.01016.78 Kantarci, 2002, 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease, J Int Neuropsychol Soc, 8, 934, 10.1017/S1355617702870084 Burn, 2003, Use of functional imaging in Parkinsonism and dementia, Mov Disord, 18, S88, 10.1002/mds.10568 Khachaturian, 2006, Diagnosis of Alzheimer's disease: two-decades of progress, J Alzheimers Dis, 9, 409, 10.3233/JAD-2006-9S346 Thompson, 2005, Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline, Proc Natl Acad Sci USA, 102, 15647, 10.1073/pnas.0502548102 Thurnher, 2005, Diffusion-tensor MR imaging of the brain in human immunodeficiency virus-positive patients, AJNR Am J Neuroradiol, 26, 2275 Walker, 2005, Imaging in neurodegenerative disorders: recent studies, Curr Opin Psychiatry, 18, 640, 10.1097/01.yco.0000184417.29082.ea Lehericy, 2007, Magnetic resonance imaging of Alzheimer's disease, Eur Radiol, 17, 347, 10.1007/s00330-006-0341-z Boska, 2005, Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease, J Neurosci, 25, 1691, 10.1523/JNEUROSCI.4364-04.2005 Block, 2002, In-vivo proton MR-spectroscopy of the human brain: assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration, Amino Acids, 23, 317, 10.1007/s00726-001-0144-0 Ackl, 2005, Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease, Neurosci Lett, 384, 23, 10.1016/j.neulet.2005.04.035 Mayhan, 2001, Regulation of blood–brain barrier permeability, Microcirculation, 8, 89 Smith, 2006, Endocytosis at the blood–brain barrier: from basic understanding to drug delivery strategies, J Drug Target, 14, 191, 10.1080/10611860600650086 Begley, 1996, The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system, J Pharm Pharmacol, 48, 136, 10.1111/j.2042-7158.1996.tb07112.x Tamai, 2000, Transporter-mediated permeation of drugs across the blood–brain barrier, J Pharm Sci, 89, 1371, 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D Fromm, 2000, P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs, Int J Clin Pharmacol Ther, 38, 69, 10.5414/CPP38069 Loscher, 2005, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases, Prog Neurobiol, 76, 22, 10.1016/j.pneurobio.2005.04.006 Minn, 1991, Drug metabolizing enzymes in the brain and cerebral microvessels, Brain Res Brain Res Rev, 16, 65, 10.1016/0165-0173(91)90020-9 Abbott, 1996, Transporting therapeutics across the blood–brain barrier, Mol Med Today, 2, 106, 10.1016/1357-4310(96)88720-X Davson, 1996, Special aspects of the blood–brain barrier, 303 Banks, 1996, Passage of peptides across the blood–brain barrier: pathophysiological perspectives, Life Sci, 59, 1923, 10.1016/S0024-3205(96)00380-3 Banks, 1997, Transport of insulin across the blood–brain barrier: saturability at euglycemic doses of insulin, Peptides, 18, 1423, 10.1016/S0196-9781(97)00231-3 Woods, 2003, Insulin and the blood–brain barrier, Curr Pharm Des, 9, 795, 10.2174/1381612033455323 Raub, 1990, Adsorptive endocytosis and membrane recycling by cultured primary bovine brain microvessel endothelial cell monolayers, J Cell Sci, 97, 127, 10.1242/jcs.97.1.127 Banks, 1994, Blood to brain and brain to blood passage of native horseradish peroxidase, wheat germ agglutinin, and albumin: pharmacokinetic and morphological assessments, J Neurochem, 62, 2404, 10.1046/j.1471-4159.1994.62062404.x Agrawal, 2006, Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis, J Exp Med, 203, 1007, 10.1084/jem.20051342 Broadwell, 1993, Serum proteins bypass the blood–brain fluid barriers for extracellular entry to the central nervous system, Exp Neurol, 120, 245, 10.1006/exnr.1993.1059 Banks, 2002, Passage of amyloid beta protein antibody across the blood–brain barrier in a mouse model of Alzheimer's disease, Peptides, 23, 2223, 10.1016/S0196-9781(02)00261-9 Kozlowski, 1992, Localization patterns for immunoglobulins and albumins in the brain suggest diverse mechanisms for their transport across the blood–brain barrier (BBB), 149, 10.1016/S0079-6123(08)62329-8 Folkman, 1964, The use of silicone rubber as a carrier for prolonged drug therapy, J Surg Res, 71, 139, 10.1016/S0022-4804(64)80040-8 Folkman, 1966, Silicone rubber: a new diffusion property useful for general anesthesia, Science, 154, 148, 10.1126/science.154.3745.148 Langer, 2001, Drug delivery. Drugs on target, Science, 293, 58, 10.1126/science.1063273 Richards Grayson, 2003, Multi-pulse drug delivery from a resorbable polymeric microchip device, Nat Mater, 2, 767, 10.1038/nmat998 Wu, 1994, In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy, J Biomed Mater Res, 28, 387, 10.1002/jbm.820280314 Lesniak, 2001, Drug delivery to tumors of the central nervous system, Curr Neurol Neurosci Rep, 1, 210, 10.1007/s11910-001-0020-z Saltzman, 1999, Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems, Pharm Res, 16, 232, 10.1023/A:1018824324275 Stroh, 2003, Diffusion of nerve growth factor in rat striatum as determined by multiphoton microscopy, Biophys J, 85, 581, 10.1016/S0006-3495(03)74502-0 Siepmann, 2006, Local controlled drug delivery to the brain: mathematical modeling of the underlying mass transport mechanisms, Int J Pharm, 314, 101, 10.1016/j.ijpharm.2005.07.027 Duncan, 2003, The dawning era of polymer therapeutics, Nat Rev Drug Discov, 2, 347, 10.1038/nrd1088 Duncan, 2006, Polymer conjugates as anticancer nanomedicines, Nat Rev Cancer, 6, 688, 10.1038/nrc1958 Gabizon, 2003, Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies, Clin Pharmacokinet, 42, 419, 10.2165/00003088-200342050-00002 Sharpe, 2002, Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma, Drugs, 62, 2089, 10.2165/00003495-200262140-00012 Gradishar, 2006, Albumin-bound paclitaxel: a next-generation taxane, Expert Opin Pharmacother, 7, 1041, 10.1517/14656566.7.8.1041 Feng, 2004, Nanoparticles of biodegradable polymers for clinical administration of paclitaxel, Curr Med Chem, 11, 413, 10.2174/0929867043455909 Kakizawa, 2002, Block copolymer micelles for delivery of gene and related compounds, Adv Drug Deliv Rev, 54, 203, 10.1016/S0169-409X(02)00017-0 Kabanov, 2002, Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery, J Control Release, 82, 189, 10.1016/S0168-3659(02)00009-3 Savic, 2003, Micellar nanocontainers distribute to defined cytoplasmic organelles, Science, 300, 615, 10.1126/science.1078192 Trentin, 2005, Non-viral gene delivery for local and controlled DNA release, J Control Release, 102, 263, 10.1016/j.jconrel.2004.09.029 Missirlis, 2005, Amphiphilic hydrogel nanoparticles. Preparation, characterization, and preliminary assessment as new colloidal drug carriers, Langmuir, 21, 2605, 10.1021/la047367s Salem, 2003, Multifunctional nanorods for gene delivery, Nat Mater, 2, 668, 10.1038/nmat974 Nayak, 2005, Soft nanotechnology with soft nanoparticles, Angew Chem Int Ed Engl, 44, 7686, 10.1002/anie.200501321 Kabanov, 1989, The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting, FEBS Lett, 258, 343, 10.1016/0014-5793(89)81689-8 Yokoyama, 1990, Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer, Cancer Res, 50, 1693 Kwon, 2003, Polymeric micelles for delivery of poorly water-soluble compounds, Crit Rev Ther Drug Carrier Syst, 20, 357, 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20 Torchilin, 2007, Micellar nanocarriers: pharmaceutical perspectives, Pharm Res, 24, 1, 10.1007/s11095-006-9132-0 Wu, 1987, Receptor-mediated in vitro gene transformation by a soluble DNA carrier system, J Biol Chem, 262, 4429, 10.1016/S0021-9258(18)61209-8 Kabanov, 1989, Increase in the transforming activity of plasmid DNA by means of its inclusion in the interpolyelectrolytic complex with a carbon-chain cation, Dokl Biochem (Dokl Akad Nauk SSSR), 306, 133 Cotten, 1990, Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels, Proc Natl Acad Sci USA, 87, 4033, 10.1073/pnas.87.11.4033 Slepnev, 1995, Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells, Bioconjug Chem, 6, 608, 10.1021/bc00035a016 Boussif, 1995, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine, Proc Natl Acad Sci USA, 92, 7297, 10.1073/pnas.92.16.7297 Read, 2005, Barriers to gene delivery using synthetic vectors, Adv Genet, 53, 19, 10.1016/S0065-2660(05)53002-5 Wagner, 2005, Targeting of polyplexes: toward synthetic virus vector systems, Adv Genet, 53, 333, 10.1016/S0065-2660(05)53013-X Kabanov, 2005, Pluronic block copolymers for gene delivery, Adv Genet, 53, 231, 10.1016/S0065-2660(05)53009-8 Ogris, 2002, Tumor-targeted gene transfer with DNA polyplexes, Somat Cell Mol Genet, 27, 85, 10.1023/A:1022988008131 Kabanov, 1995, Water-soluble block polycations as carriers for oligonucleotide delivery, Bioconjug Chem, 6, 639, 10.1021/bc00036a001 Harada, 1995, Formation of polyion complex micelles in an aqueous milieu from a pair of oppositely-charged block copolymers with poly(ethylene glycol) segments, Macromolecules, 28, 5294, 10.1021/ma00119a019 van Nostrum, 2004, Polymeric micelles to deliver photosensitizers for photodynamic therapy, Adv Drug Deliv Rev, 56, 9, 10.1016/j.addr.2003.07.013 Oh, 2006, Block ionomer complexes as prospective nanocontainers for drug delivery, J Control Release, 115, 9, 10.1016/j.jconrel.2006.06.030 Vinogradov, 1999, Poly(ethylene glycol)-polyethyleneimine nanogel particles: novel drug delivery systems for antisense oligonucleotides, Coll Surf B Biointerfaces, 16, 291, 10.1016/S0927-7765(99)00080-6 McAllister, 2002, Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents, J Am Chem Soc, 124, 15198, 10.1021/ja027759q Vinogradov, 2004, Nanogels for oligonucleotide delivery to the brain, Bioconjug Chem, 15, 50, 10.1021/bc034164r Kazakov, 2006, Ion concentration of external solution as a characteristic of micro- and nanogel ionic reservoirs, J Phys Chem B Condens Matter Mater Surf Interfaces Biophys, 110, 15107 Soni, 2006, Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels, J Drug Target, 14, 87, 10.1080/10611860600635608 Danson, 2004, Phase I dose escalation and pharmacokinetic study of Pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer, Br J Cancer, 90, 2085, 10.1038/sj.bjc.6601856 Matsumura, 2004, Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin, Br J Cancer, 91, 1775, 10.1038/sj.bjc.6602204 Kim, 2004, Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies, Clin Cancer Res, 10, 3708, 10.1158/1078-0432.CCR-03-0655 Matsumura, 2006, Micelle carrier system in clinical trial, Nippon Rinsho, 64, 316 Armstrong A., et al. SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: a phase II window study. In: Journal of Clinical Oncology. ASCO annual meeting proceedings, Part I, vol. 24. 2006. p. 4080 Helms, 2006, Chemistry. Dendrimers at work, Science, 313, 929, 10.1126/science.1130639 Tao, 2006, Novel amphiphilic macromolecules and their in vitro characterization as stabilized micellar drug delivery systems, J Colloid Interface Sci, 298, 102, 10.1016/j.jcis.2005.12.018 Pochan, 2004, Toroidal triblock copolymer assemblies, Science, 306, 94, 10.1126/science.1102866 Bronich, 2005, Polymer micelle with cross-linked ionic core, J Am Chem Soc, 127, 8236, 10.1021/ja043042m Wang, 2005, Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier, Bioconjug Chem, 16, 397, 10.1021/bc049784m O’Reilly, 2006, Cross-linked block copolymer micelles: functional nanostructures of great potential and versatility, Chem Soc Rev, 35, 1068, 10.1039/b514858h in het Panhuis, 2003, Vaccine delivery by carbon nanotubes, Chem Biol, 10, 897, 10.1016/j.chembiol.2003.10.005 Cai, 2005, Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing, Nat Methods, 2, 449, 10.1038/nmeth761 Dzenis, 2004, Material science. Spinning continuous fibers for nanotechnology, Science, 304, 1917, 10.1126/science.1099074 Chua, 2006, Surface-aminated electrospun nanofibers enhance adhesion and expansion of human umbilical cord blood hematopoietic stem/progenitor cells, Biomaterials, 27, 6043, 10.1016/j.biomaterials.2006.06.017 Brewster, 2004, The use of polymer-based electrospun nanofibers containing amorphous drug dispersions for the delivery of poorly water-soluble pharmaceuticals, Pharmazie, 59, 387 Xu, 2004, Electrospun nanofiber fabrication as synthetic extracellular matrix and its potential for vascular tissue engineering, Tissue Eng, 10, 1160, 10.1089/ten.2004.10.1160 Huwyler, 1996, Brain drug delivery of small molecules using immunoliposomes, Proc Natl Acad Sci USA, 93, 14164, 10.1073/pnas.93.24.14164 Kozubek, 2000, Liposomal drug delivery, a novel approach: PLARosomes, Acta Biochim Pol, 47, 639, 10.18388/abp.2000_3985 Voinea, 2002, Designing of ‘intelligent’ liposomes for efficient delivery of drugs, J Cell Mol Med, 6, 465, 10.1111/j.1582-4934.2002.tb00450.x Gabizon, 1994, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res, 54, 987 Papaldo, 2006, A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease, Ann Oncol, 17, 630, 10.1093/annonc/mdj110 Umezawa, 1988, Liposome targeting to mouse brain: mannose as a recognition marker, Biochem Biophys Res Commun, 153, 1038, 10.1016/S0006-291X(88)81333-0 Rousseau, 1999, Early detection of liposome brain localization in rat experimental allergic encephalomyelitis, Exp Brain Res, 125, 255, 10.1007/s002210050681 Shi, 2001, Brain-specific expression of an exogenous gene after i.v. administration, Proc Natl Acad Sci USA, 98, 12754, 10.1073/pnas.221450098 Mora, 2002, Design and characterization of liposomes containing long-chain N-acylPEs for brain delivery: penetration of liposomes incorporating GM1 into the rat brain, Pharm Res, 19, 1430, 10.1023/A:1020440229102 Thole, 2002, Uptake of cationzied albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries, J Drug Target, 10, 337, 10.1080/10611860290031840 Wu, 2002, Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood–brain barrier drug delivery system, J Drug Target, 10, 239, 10.1080/10611860290022679 Zhang, 2003, Marked enhancement in gene expression by targeting the human insulin receptor, J Gene Med, 5, 157, 10.1002/jgm.333 Schmidt, 2003, Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis, Brain, 126, 1895, 10.1093/brain/awg176 Omori, 2003, Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin, Neurol Res, 25, 275, 10.1179/016164103101201508 Aoki, 2004, Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model, Int J Hyperthermia, 20, 595, 10.1080/02656730410001703186 Gosk, 2004, Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion, J Cereb Blood Flow Metab, 24, 1193, 10.1097/01.WCB.0000135592.28823.47 Chekhonin, 2005, PEGylated immunoliposomes directed against brain astrocytes, Drug Deliv, 12, 1, 10.1080/10717540590889556 Pardridge, 2005, Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy, NeuroRx, 2, 129, 10.1602/neurorx.2.1.129 Pardridge, 1999, Vector-mediated drug delivery to the brain, Adv Drug Deliv Rev, 36, 299, 10.1016/S0169-409X(98)00087-8 Pardridge, 1987, Human blood–brain barrier transferrin receptor, Metabolism, 36, 892, 10.1016/0026-0495(87)90099-0 Huwyler, 2002, By-passing of P-glycoprotein using immunoliposomes, J Drug Target, 10, 73, 10.1080/10611860290007559 Wu, 1996, Pharmacokinetics and blood–brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system, J Pharmacol Exp Ther, 276, 206 Coloma, 2000, Transport across the primate blood–brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor, Pharm Res, 17, 266, 10.1023/A:1007592720793 Moghimi, 1990, Physiopathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow, Crit Rev Ther Drug Carrier Syst, 7, 187 Moghimi, 2003, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog Lipid Res, 42, 463, 10.1016/S0163-7827(03)00033-X Gref, 1994, Biodegradable long-circulating polymeric nanospheres, Science, 263, 1600, 10.1126/science.8128245 Peracchia, 1998, Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer, Pharm Res, 15, 550, 10.1023/A:1011973625803 Torchilin, 1998, Polymer-coated long-circulating microparticulate pharmaceuticals, J Microencapsul, 15, 1, 10.3109/02652049809006831 Calvo, 2002, Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat, Eur J Neurosci, 15, 1317, 10.1046/j.1460-9568.2002.01967.x Lemieux, 2000, Block and graft copolymers and NanoGel copolymer networks for DNA delivery into cell, J Drug Target, 8, 91, 10.3109/10611860008996855 Gupta, 2003, Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis, IEEE Trans Nanobiosci, 2, 255, 10.1109/TNB.2003.820279 Kreuter, 2004, Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain, J Nanosci Nanotechnol, 4, 484, 10.1166/jnn.2003.077 Cui, 2005, Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases, Eur J Pharm Biopharm, 59, 263, 10.1016/j.ejpb.2004.07.009 Calvo, 2001, Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery, Pharm Res, 18, 1157, 10.1023/A:1010931127745 Kreuter, 2003, Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles, Pharm Res, 20, 409, 10.1023/A:1022604120952 Steiniger, 2004, Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles, Int J Cancer, 109, 759, 10.1002/ijc.20048 Olivier, 1999, Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity, Pharm Res, 16, 1836, 10.1023/A:1018947208597 Friese, 2000, Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system, Eur J Pharm Biopharm, 49, 103, 10.1016/S0939-6411(99)00073-9 Hyuk Im, 2005, Polymer hollow particles with controllable holes in their surfaces, Nat Mater, 4, 671, 10.1038/nmat1448 Yang, 2004, Nanoparticle-based in vivo investigation on blood–brain barrier permeability following ischemia and reperfusion, Anal Chem, 76, 4465, 10.1021/ac035491v Kreuter, 2001, Nanoparticulate systems for brain delivery of drugs, Adv Drug Deliv Rev, 47, 65, 10.1016/S0169-409X(00)00122-8 Jacobs, 2000, Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide, Int J Pharm, 196, 161, 10.1016/S0378-5173(99)00412-3 Rabinow, 2004, Nanosuspensions in drug delivery, Nat Rev Drug Discov, 3, 785, 10.1038/nrd1494 Friedrich, 2003, Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS-based nanosuspensions, Eur J Pharm Biopharm, 56, 111, 10.1016/S0939-6411(03)00043-2 Friedrich, 2005, Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS), Int J Pharm, 305, 167, 10.1016/j.ijpharm.2005.09.007 Muller, 2001, Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future, Adv Drug Deliv Rev, 47, 3, 10.1016/S0169-409X(00)00118-6 Kataoka, 2001, Block copolymer micelles for drug delivery: design, characterization and biological significance, Adv Drug Deliv Rev, 47, 113, 10.1016/S0169-409X(00)00124-1 Kabanov, 2002, Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers, Crit Rev Ther Drug Carrier Syst, 19, 1, 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10 Torchilin, 2004, Targeted polymeric micelles for delivery of poorly soluble drugs, Cell Mol Life Sci, 61, 2549, 10.1007/s00018-004-4153-5 Allen, 2004, Drug delivery systems: entering the mainstream, Science, 303, 1818, 10.1126/science.1095833 Aliabadi, 2006, Polymeric micelles for drug delivery, Expert Opin Drug Deliv, 3, 139, 10.1517/17425247.3.1.139 Torchilin, 2002, PEG-based micelles as carriers of contrast agents for different imaging modalities, Adv Drug Deliv Rev, 54, 235, 10.1016/S0169-409X(02)00019-4 Kabanov, 1992, A new class of drug carriers: micelles of poly(oxyethilene)-poly(oxupropilene) block copolymers as microcontainers for drug targeting from blood in brain, J Contr Release, 22, 141, 10.1016/0168-3659(92)90199-2 Batrakova, 1998, Effects of Pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells, Pharm Res, 15, 1525, 10.1023/A:1011942814300 Nguyen, 2000, Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents, Gene Ther, 7, 126, 10.1038/sj.gt.3301052 Zhang, 2003, Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer, J Control Release, 93, 141, 10.1016/j.jconrel.2003.05.002 Jaturanpinyo, 2004, Preparation of bionanoreactor based on core-shell structured polyion complex micelles entrapping trypsin in the core cross-linked with glutaraldehyde, Bioconjug Chem, 15, 344, 10.1021/bc034149m Harada, 1999, Novel polyion complex micelles entrapping enzyme molecules in the core. 2. Characterization of the micelles prepared at nonstoichiometric mixing ratios, Langmuir, 15, 4208, 10.1021/la981087t Harada, 2003, Switching by pulse electric field of the elevated enzymatic reaction in the core of polyion complex micelles, J Am Chem Soc, 125, 15306, 10.1021/ja038572h Harada, 1999, Chain length recognition: core-shell supramolecular assembly from oppositely charged block copolymers, Science, 283, 65, 10.1126/science.283.5398.65 Bronich, 1997, Soluble complexes from poly(ethylene oxide)-block-polymethacrylate anions and N-alkylpyridinium cations, Macromolecules, 30, 3519, 10.1021/ma970197o Bronich, 1998, Self-assembly in mixtures of poly(ethylene oxide)-graft-poly(ethyleneimine) and alkyl sulfates, Langmuir, 14, 6101, 10.1021/la980530x Bronich, 1999, Novel drug delivery systems based on the complexes of block ionomers and surfactants of opposite charge, Colloids Surf B, 16, 243, 10.1016/S0927-7765(99)00075-2 Bronich, 2000, Effects of block length and structure of surfactant on self-assembly and solution behavior of block ionomer complexes, Langmuir, 16, 481, 10.1021/la990628r Solomatin, 2003, Environmentally responsive nanoparticles from block ionomer complexes: effect of pH and ionic strength, Langmuir, 19, 8069, 10.1021/la030015l Solomatin, 2004, Colloidal stability of aqueous dispersions of block ionomer complexes: effects of temperature and salt, Langmuir, 20, 2066, 10.1021/la034895f Solomatin, 2007, Nanomaterials from ionic blockcopolymers and single-, double- and triple-tail surfactants, Langmuir, 23, 2838, 10.1021/la062693o Roy, 1999, Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides, Nat Biotechnol, 17, 476, 10.1038/8654 Harada-Shiba, 2002, Polyion complex micelles as vectors in gene therapy—pharmacokinetics and in vivo gene transfer, Gene Ther, 9, 407, 10.1038/sj.gt.3301665 Junghans, 2005, Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides, Eur J Pharm Biopharm, 60, 287, 10.1016/j.ejpb.2005.01.006 Liu, 1999, Unimolecular micelles: synthesis and characterization of amphiphilic polymer systems, J Polym Sci Part A Polym Chem, 37, 703, 10.1002/(SICI)1099-0518(19990315)37:6<703::AID-POLA5>3.0.CO;2-O Liu, 2000, Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents, J Control Release, 65, 121, 10.1016/S0168-3659(99)00245-X Iijima, 1999, Core-polymerized reactive micelles from heterotelechelic amphiphilic block copolymers, Macromolecules, 32, 1140, 10.1021/ma9815962 Turner, 2004, Nanoscale cage-like structures derived from polyisoprene-containing shell cross-linked nanoparticle templates, Nano Lett, 4, 683, 10.1021/nl0497981 Ma, 2001, Two-dimensional, shell-cross-linked nanoparticle arrays, J Am Chem Soc, 123, 4627, 10.1021/ja0156542 Bontha, 2006, Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs, J Control Release, 114, 163, 10.1016/j.jconrel.2006.06.015 Bronich, 2006, Template-assisted synthesis of nanogels from Pluronic-modified poly(acrylic acid), J Drug Targeting, 14, 357, 10.1080/10611860600833781 Bronich, 2002, Synthesis of vesicles on polymer template, J Am Chem Soc, 124, 11872, 10.1021/ja020509p Vinogradov, 2005, Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs, J Control Release, 107, 143, 10.1016/j.jconrel.2005.06.002 Vinogradov, 2005, Cross-linked polymeric nanogel formulations of 5′-triphosphates of nucleoside analogues: role of the cellular membrane in drug release, Mol Pharm, 2, 449, 10.1021/mp0500364 Vinogradov, 2002, Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells, Adv Drug Deliv Rev, 54, 135, 10.1016/S0169-409X(01)00245-9 Che, 1998, Chemical vapor deposition based synthesis of carbon nanotubes and nanofibers using a template method, Chem Mater, 10, 260, 10.1021/cm970412f Guler, 2005, Enhanced oligonucleotide binding to self-assembled nanofibers, Bioconjug Chem, 16, 501, 10.1021/bc050053b Bull, 2005, Self-assembled peptide amphiphile nanofibers conjugated to MRI contrast agents, Nano Lett, 5, 1, 10.1021/nl0484898 Muller, 2005, Respiratory toxicity of multi-wall carbon nanotubes, Toxicol Appl Pharmacol, 207, 221, 10.1016/j.taap.2005.01.008 Lange, 2003, Carbon arc plasma as a source of nanotubes: emission spectroscopy and formation mechanism, J Nanosci Nanotechnol, 3, 51, 10.1166/jnn.2003.191 Fong, 1999, Beaded nanofibers formed during electrospinning, Polymer, 40, 4585, 10.1016/S0032-3861(99)00068-3 Abidian M, Martin D. Controlled release of an anti-inflammatory drug using conducting polymer nanotubes for neural prosthetic applications. In: MRS symposium. San Francisco; 2005. p. 1. Haensler, 1993, Polyamidoamine cascade polymers mediate efficient transfection of cells in culture, Bioconjug Chem, 4, 372, 10.1021/bc00023a012 Kukowska-Latallo, 1996, Efficient transfer of genetic material into mammalian cells using starburst polyamidoamine dendrimers, Proc Natl Acad Sci USA, 93, 4897, 10.1073/pnas.93.10.4897 Nishiyama, 2005, Light-induced gene transfer from packaged DNA enveloped in a dendrimeric photosensitizer, Nat Mater, 4, 934, 10.1038/nmat1524 Kobayashi, 2005, Nano-sized MRI contrast agents with dendrimer cores, Adv Drug Deliv Rev, 57, 2271, 10.1016/j.addr.2005.09.016 Lee, 2006, A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas, Proc Natl Acad Sci USA, 103, 16649, 10.1073/pnas.0607705103 Talanov, 2006, Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging, Nano Lett, 6, 1459, 10.1021/nl060765q Yang, 2006, Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4, Clin Cancer Res, 12, 3792, 10.1158/1078-0432.CCR-06-0141 Wu, 2006, Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates, Mol Cancer Ther, 5, 52, 10.1158/1535-7163.MCT-05-0325 Kitchens, 2005, Transepithelial and endothelial transport of poly (amidoamine) dendrimers, Adv Drug Deliv Rev, 57, 2163, 10.1016/j.addr.2005.09.013 Daleke, 1990, Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay, Biochim Biophys Acta, 1024, 352, 10.1016/0005-2736(90)90365-U Fujiwara, 1996, Receptor-mediated endocytosis of poly(acrylic acid)-conjugated liposomes by macrophages, Biochim Biophys Acta, 1278, 59, 10.1016/0005-2736(95)00183-2 Jain, 2003, RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting, Int J Pharm, 261, 43, 10.1016/S0378-5173(03)00269-2 Khan, 2005, Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model, J Antimicrob Chemother, 55, 223, 10.1093/jac/dkh522 Perry, 1995, Inflammation in the nervous system, Curr Opin Neurobiol, 5, 636, 10.1016/0959-4388(95)80069-7 Kuby, 1994, Immunology Steinfeld, 2006, T lymphocytes as potential therapeutic drug carrier for cancer treatment, Int J Pharm, 311, 229, 10.1016/j.ijpharm.2005.12.040 Audran, 1995, Fate of mouse macrophages radiolabelled with PKH-95 and injected intravenously, Nucl Med Biol, 22, 817, 10.1016/0969-8051(95)00013-N Carver, 2003, Caveolae: mining little caves for new cancer targets, Nat Rev Cancer, 3, 571, 10.1038/nrc1146 Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int J Pharm, 307, 93, 10.1016/j.ijpharm.2005.10.010 Panyam, 2002, Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery, Faseb J, 16, 1217, 10.1096/fj.02-0088com Manjunath, 2006, Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration, J Drug Target, 14, 632, 10.1080/10611860600888850 Campbell, 2006, Tumor physiology and delivery of nanopharmaceuticals, Anticancer Agents Med Chem, 6, 503, 10.2174/187152006778699077 Paul, 1998, Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice, J Drug Target, 5, 481, 10.3109/10611869808997874 Gibbs, 2005, Liposomal amphotericin B: clinical experience and perspectives, Expert Rev Anti Infect Ther, 2, 167, 10.1586/14787210.3.2.167 Wolburg, 2005, Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact, Acta Neuropathol (Berlin), 109, 181, 10.1007/s00401-004-0928-x Gorantla, 2006, Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery, J Leukoc Biol, 80, 1165, 10.1189/jlb.0206110 Dou, 2006, Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery, Blood, 108, 2827, 10.1182/blood-2006-03-012534 Dou, 2007, Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages, Virology, 358, 148, 10.1016/j.virol.2006.08.012 Zhang, 2004, The effect of RMP-7 and its derivative on transporting evens blue liposomes into the brain, Drug Deliv, 11, 301, 10.1080/10717540490494078 Pardridge, 1998, Introduction to the blood–brain barrier, 486 Begley, 2004, ABC transporters and the blood–brain barrier, Curr Pharm Des, 10, 1295, 10.2174/1381612043384844 Tsuji, 1997, Blood–brain barrier function of P-glycoprotein, Adv Drug Deliv Rev, 25, 287, 10.1016/S0169-409X(97)00504-8 Kim, 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J Clin Invest, 101, 289, 10.1172/JCI1269 Perloff, 2004, Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats, Xenobiotica, 34, 133, 10.1080/00498250310001630215 Uhr, 2000, Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood–brain barrier deficiency due to mdr1a P-glycoprotein gene disruption, Neuropsychopharmacology, 22, 380, 10.1016/S0893-133X(99)00095-0 Moriki, 2004, Involvement of P-glycoprotein in blood–brain barrier transport of pentazocine in rats using brain uptake index method, Biol Pharm Bull, 27, 932, 10.1248/bpb.27.932 Potschka, 2002, P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: evidence from microdialysis experiments in rats, Neurosci Lett, 327, 173, 10.1016/S0304-3940(02)00423-8 Miyama, 1998, P-glycoprotein-mediated transport of itraconazole across the blood–brain barrier, Antimicrob Agents Chemother, 42, 1738, 10.1128/AAC.42.7.1738 Tsuji, 1998, P-glycoprotein-mediated efflux transport of anticancer drugs at the blood–brain barrier, Ther Drug Monit, 20, 588, 10.1097/00007691-199810000-00024 Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat Rev Cancer, 2, 48, 10.1038/nrc706 Kemper, 2003, Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein, Clin Cancer Res, 9, 2849 Kemper, 2004, The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice, Cancer Chemother Pharmacol, 53, 173, 10.1007/s00280-003-0720-y Woodcock, 1990, Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs, Cancer Res, 50, 4199 Woodcock, 1992, Reversal of multidrug resistance by surfactants, Br J Cancer, 66, 62, 10.1038/bjc.1992.217 Nerurkar, 1996, The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system, Pharm Res, 13, 528, 10.1023/A:1016033702220 Buckingham, 1996, Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters, Int J Cancer, 65, 74, 10.1002/(SICI)1097-0215(19960103)65:1<74::AID-IJC13>3.0.CO;2-I Alakhov, 1996, Hypersensitization of multidrug resistant human ovarian carcinoma cells by Pluronic P85 block copolymer, Bioconjug Chem, 7, 209, 10.1021/bc950093n Batrakova, 1999, Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers, Pharm Res, 16, 1366, 10.1023/A:1018990706838 Kabanov, 2003, Pluronic block copolymers as modulators of drug efflux transporter activity in the blood–brain barrier, Adv Drug Deliv Rev, 55, 151, 10.1016/S0169-409X(02)00176-X Miller, 1997, Interactions of Pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption, Bioconjugate Chem, 8, 649, 10.1021/bc970118d Batrakova, 2001, Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies, J Pharmacol Exp Ther, 296, 551 Witt, 2002, Pluronic p85 block copolymer enhances opioid peptide analgesia, J Pharmacol Exp Ther, 303, 760, 10.1124/jpet.102.039545 Batrakova, 1999, Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effect in MDR cancer cells, Pharm Res, 16, 1373, 10.1023/A:1018942823676 Batrakova, 2003, Optimal structure requirements for Pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells, J Pharmacol Exp Ther, 304, 845, 10.1124/jpet.102.043307 Batrakova, 2001, Mechanism of Pluronic effect on P-glycoprotein efflux system in blood–brain barrier: contributions of energy depletion and membrane fluidization, J Pharmacol Exp Ther, 299, 483 Bacso, 2004, Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein, Cytometry A, 61, 105, 10.1002/cyto.a.20081 Batrakova, 2004, Effect of Pluronic P85 on ATPase activity of drug efflux transporters, Pharm Res, 21, 2226, 10.1007/s11095-004-7675-5 Batrakova, 2001, Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion, Br J Cancer, 85, 1987, 10.1054/bjoc.2001.2165 Kabanov, 2003, An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers, J Control Release, 91, 75, 10.1016/S0168-3659(03)00211-6 Batrakova, 2003, Sensitization of cells overexpressing multidrug-resistant proteins by Pluronic P85, Pharm Res, 20, 1581, 10.1023/A:1026179132599 Batrakova, 2004, Effects of Pluronic P85 on GLUT1 and MCT1 transporters in the blood–brain barrier, Pharm Res, 21, 1993, 10.1023/B:PHAM.0000048189.79606.6e Zhang X, et al. Effect of Pluronic P85 on amino acid transporters in the blood brain barrier. Pharm Res, 2007; in press. Valle JW, et al. A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus. In: Journal of Clinical Oncology. ASCO annual meeting proceedings (post-meeting edition), vol. 22. 2004. p. 4195. Witt, 2002, Pluronic p85 block copolymer enhances opioid peptide analgesia, J Pharmacol Exp Ther, 303, 760, 10.1124/jpet.102.039545 Spitzenberger, 2006, Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis, J Cereb Blood Flow Metab, 27, 1033, 10.1038/sj.jcbfm.9600414 Lee, 1991 Kumagai, 1987, Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood–brain barrier transport, J Biol Chem, 262, 15214, 10.1016/S0021-9258(18)48160-4 Triguero, 1989, Blood–brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein, Proc Natl Acad Sci USA, 86, 4761, 10.1073/pnas.86.12.4761 Triguero, 1991, Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate, J Pharmacol Exp Ther, 258, 186 Bickel, 2001, Delivery of peptides and proteins through the blood–brain barrier, Adv Drug Deliv Rev, 46, 247, 10.1016/S0169-409X(00)00139-3 Frank, 1986, Insulin binding to the blood–brain barrier in the streptozotocin diabetic rat, J Neurochem, 47, 405, 10.1111/j.1471-4159.1986.tb04516.x Duffy, 1987, Blood–brain barrier transcytosis of insulin in developing rabbits, Brain Res, 420, 32, 10.1016/0006-8993(87)90236-8 Friden, 1991, Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood–brain barrier, Proc Natl Acad Sci USA, 88, 4771, 10.1073/pnas.88.11.4771 Zhang, 2001, Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin, Brain Res, 889, 49, 10.1016/S0006-8993(00)03108-5 Zhang, 2001, Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood–brain barrier drug targeting system, Stroke, 32, 1378, 10.1161/01.STR.32.6.1378 Song, 2002, Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood–brain barrier delivery vector, J Pharmacol Exp Ther, 301, 605, 10.1124/jpet.301.2.605 Schwarze, 2000, Protein transduction: unrestricted delivery into all cells?, Trends Cell Biol, 10, 290, 10.1016/S0962-8924(00)01771-2 Wadia, 2005, Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer, Adv Drug Deliv Rev, 57, 579, 10.1016/j.addr.2004.10.005 Derossi, 1994, The third helix of the Antennapedia homeodomain translocates through biological membranes, J Biol Chem, 269, 10444, 10.1016/S0021-9258(17)34080-2 Vives, 1997, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J Biol Chem, 272, 16010, 10.1074/jbc.272.25.16010 Wender, 2000, The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters, Proc Natl Acad Sci USA, 97, 13003, 10.1073/pnas.97.24.13003 Tyagi, 2001, Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans, J Biol Chem, 276, 3254, 10.1074/jbc.M006701200 Wadia, 2004, Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis, Nat Med, 10, 310, 10.1038/nm996 Toborek, 2003, HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium, J Neurochem, 84, 169, 10.1046/j.1471-4159.2003.01543.x Toborek, 2005, Mechanisms of the blood–brain barrier disruption in HIV-1 infection, Cell Mol Neurobiol, 25, 181, 10.1007/s10571-004-1383-x Price, 2005, HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells, Brain Res, 1045, 57, 10.1016/j.brainres.2005.03.031 D’Aversa, 2005, NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation, J Neurosci Res, 81, 436, 10.1002/jnr.20486 Banks, 2006, The blood–brain barrier in neuroAIDS, Curr HIV Res, 4, 259, 10.2174/157016206777709447 Banks, 2005, Permeability of the blood–brain barrier to HIV-1 Tat, Exp Neurol, 193, 218, 10.1016/j.expneurol.2004.11.019 Santra S, et al. Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem Commun (Camb) 2005:3144–6. Snyder, 2004, Cell penetrating peptides in drug delivery, Pharm Res, 21, 389, 10.1023/B:PHAM.0000019289.61978.f5 Kilic, 2003, Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice, Stroke, 34, 1304, 10.1161/01.STR.0000066869.45310.50 Kilic, 2006, TAT fusion proteins against ischemic stroke: current status and future perspectives, Front Biosci, 11, 1716, 10.2741/1917 Dietz, 2006, Application of a blood–brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease, Brain Res, 1082, 61, 10.1016/j.brainres.2006.01.083 Wu, 2006, A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase, Biochem Biophys Res Commun, 346, 1, 10.1016/j.bbrc.2006.03.247 Andrade, 2006, Protein therapy for Unverricht–Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple?, Epilepsy Res, 72, 75, 10.1016/j.eplepsyres.2006.07.009 Cantara, 2007, TAT-BH4 counteracts Abeta toxicity on capillary endothelium, FEBS Lett, 581, 702, 10.1016/j.febslet.2007.01.037 Vaags, 2005, HIV TAT variants differentially influence the production of glucocerebrosidase in Sf9 cells, Genet Mol Res, 4, 491 Kabanov, 1987, Transformation of water-soluble enzymes into membrane active form by chemical modification, Ann N Y Acad Sci, 501, 63, 10.1111/j.1749-6632.1987.tb45685.x Kabanov, 1989, Lipid modification of proteins and their membrane transport, Protein Eng, 3, 39, 10.1093/protein/3.1.39 Hashimoto, 1989, Synthesis of palmitoyl derivatives of insulin and their biological activities, Pharm Res, 6, 171, 10.1023/A:1015992828666 Alakhov, 1990, Increasing cytostatic effects of ricin A chain and Staphylococcus aureus enterotoxin A through in vitro hydrophobization with fatty acid residues, Biotechnol Appl Biochem, 12, 94 Colsky, 1991, Palmitate-derivatized antibodies can specifically "arm" macrophage effector cells for ADCC, J Leukoc Biol, 49, 1, 10.1002/jlb.49.1.1 Melik-Nubarov, 1993, Interaction of hydrophobized antiviral antibodies with influenza virus infected MDCK cells, Biochem Mol Biol Int, 29, 939 Ekrami, 1995, Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides, FEBS Lett, 371, 283, 10.1016/0014-5793(95)00910-2 Chopineau, 1998, Monoacylation of ribonuclease A enables its transport across an in vitro model of the blood–brain barrier, J Control Release, 56, 231, 10.1016/S0168-3659(98)00091-1 Kozlova, 1999, Catalytic properties and conformation of hydrophobized alpha-chymotrypsin incorporated into a bilayer lipid membrane, FEBS Lett, 461, 141, 10.1016/S0014-5793(99)01449-0 Kabanov, 1989, Fatty acid acylated antibodies against virus suppress its reproduction in cells, FEBS Lett, 250, 238, 10.1016/0014-5793(89)80729-X Chekhonin, 1991, Fatty acid acylated FAB-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain, FEBS Lett, 287, 149, 10.1016/0014-5793(91)80037-4 Robert, 1993, Fatty acid acylation of RNase A using reversed micelles as microreactors, Biochem Biophys Res Commun, 196, 447, 10.1006/bbrc.1993.2270 Robert, 1995, Optimization of RNase A artificial hydrophobization in AOT reversed micelles, Ann N Y Acad Sci, 750, 121, 10.1111/j.1749-6632.1995.tb19939.x Kabanov, 1992, Enhancement of macromolecule penetration into cells and nontraditional drug delivery systems, Sov Sci Rev Ser D Physicochem Biol, 11, 1 Chekhonin, 1995, Transport of hydrophobized fragments of antibodies through the blood–brain barrier, Neuroreport, 7, 129 Batrakova, 2005, Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery, Bioconjug Chem, 16, 793, 10.1021/bc049730c